CliffBio
small molecule

ANDRODERM

TESTOSTERONE

Loss of exclusivity—loss of exclusivity
CompanyAbbVie Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand nameANDRODERM
Active ingredientTESTOSTERONE
Strength5MG/24HR
Dosage formFILM, EXTENDED RELEASE
RouteTRANSDERMAL
ModalitySmall molecule
FDA approvalMay 1997
Marketing statusDISCN

More from AbbVie Inc.

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

ANDRODERM patent cliff — loss of exclusivity — | CliffBio